Silexion Therapeutics Corp
Silexion Therapeutics is a clinical-stage biotechnology company developing treatments for cancers driven by KRAS mutations. Its platform uses small interfering RNA to silence the KRAS gene and prevent production of the associated protein. The lead candidate, SIL204, is a second-generation siRNA designed to target mutated KRAS. The company is initially focused on locally advanced pancreatic cancer, evaluating SIL204 with standard chemotherapy through an Integrated Treatment Regimen that combines injection into the tumor with subcutaneous administration. Silexion also developed siG12D-LODER, a first-generation siRNA product candidate delivered directly into tumors, which has undergone Phase 1 and Phase 2 studies. The company’s activities include drug discovery and development; it relies on third-party manufacturers to produce drug substances and products for clinical trials. Its business is primarily conducted through its Israeli subsidiary, Silexion Therapeutics Ltd. Silexion is headquartered in Ramat Gan, Israel.
No SEC Form 4 filings for $SLXN in the last 30 days.
See all $SLXN insider activity →Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Silexion Therapeutics Announces 1-for-24 Reverse Share Split Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its ma
Silexion Therapeutics (SLXN) announced a 1-for-24 reverse stock split effective after Tuesday's market close to comply with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis begins Wednesday. The company aims to enhance market position and support growth initiatives, including equity financings. SLXN is a clinical-stage biotech developing RNA interference therapies for KRAS-driven cancers.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on October 19, 2026 and reconvened on October 26, 2026 (the “ Meeting ”), the shareholders of t
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning SLXN (Silexion Therapeutics Corp). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent SLXN coverage spans corporate actions, technology and financial news.
The reverse split should lift the share price above the $1 minimum, reducing volatility and potentially attracting a broader investor base.
The reverse split consolidates shares, potentially lifting the share price above the $1 minimum and improving liquidity, but does not change market cap.
Capital increase may dilute existing shareholders; reverse split could improve per-share price perception.
The trial initiation signals progress for Silexion's lead RNAi candidate, potentially boosting investor sentiment.
Strong preclinical results may boost investor confidence and drive further upside.
AlphAI scores every news story that mentions SLXN with an AI model for sentiment and relevance, and aggregates insider trades from Silexion Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Silexion Therapeutics Announces 1-for-24 Reverse Share Split Trading on a split-adjusted basis will begin at market open on November 11, 2026. This adjustment is expected to help Silexion regain compliance with the Nasdaq minimum bid price requirement, enhance its ma
Silexion Therapeutics (SLXN) announced a 1-for-24 reverse stock split effective after Tuesday's market close to comply with Nasdaq's minimum bid price requirement. Trading on a split-adjusted basis begins Wednesday. The company aims to enhance market position and support growth initiatives, including equity financings. SLXN is a clinical-stage biotech developing RNA interference therapies for KRAS-driven cancers.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on October 19, 2026 and reconvened on October 26, 2026 (the “ Meeting ”), the shareholders of t
Silexion Therapeutics (SLXN) dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The trial combines SIL204 with standard chemotherapy. The study is being conducted at Tel Aviv Sourasky Medical Center and will expand to other sites in Israel and Germany. SIL204 is administered via a dual-route delivery strategy. The company aims to evaluate the potential of SIL204 to improve patient outcomes.
Biotech stocks SLXN, SMMT, IOVA, NTHI rose on Sept 29, 2026, due to positive developments. SLXN surged 30% after preclinical data. SMMT gained 6% from AstraZeneca's $2.0B investment. IOVA rose 34% on raised revenue guidance. NTHI increased 7.59% ahead of FDA meeting.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 28, 2026, Silexion Therapeutics Corp (“ Silexion ” or the “ Company ”) entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (each a “ Holder ”) of 3,216,928 of the Com
Biotech stocks SLXN and SMMT rose premarket. SLXN gained on positive preclinical data, while SMMT jumped after a $2B equity investment from AZN. NIVF and QURE declined.
Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.
Silexion Therapeutics (SLXN) reported positive findings from a study on SIL204, its RNAi candidate for KRAS-driven cancers. The study showed SIL204 utilizes lipoproteins for cellular delivery and potent gene silencing. The company is advancing SIL204 in a Phase 2/3 trial for pancreatic cancer and continues site initiation and patient screening. SLXN's stock is up 1.84% to $0.26.
Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery
